ArticleBMC genomics2015
Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris.
Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 1 synthesis or guideline pooled it, 243 citations in OpenAlex.
- Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen.MicrobiologyOpen · 2018Pooled it
- Micafungin microevolution inVirulence · 2026Article
- Review
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Susceptibility of Candida auris isolates to antifungal agents: perspectives from whole-genome sequencing and phenotypic testing.BMC microbiology · 2026Article
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- UnderstandingJournal of medical microbiology · 2026Review
- Treatment Options and Antifungal Resistance in PediatricMicroorganisms · 2026Review
- Tackling a global threat: a clinical scenario-based framework for preventing and managingFrontiers in cellular and infection microbiology · 2026Review
- Antifungal and anti-virulence activities of cinnamon, thyme, and clove essential oils againstFrontiers in pharmacology · 2026Article
- Circulation of fluconazole-resistant Candida auris in Peru confirmed by genomic analysis.Memorias do Instituto Oswaldo Cruz · 2026Article
- Managing Candida auris in dialysis units: challenges, strategies, and future directions.International urology and nephrology · 2025Review
- Global Stress Responses Identify the Functionally Divergent Regulators Required forExploration (Beijing, China) · 2025Article
- A study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand.Scientific reports · 2025Article
- The Role of Drug Resistance in Candida Inflammation and Fitness.Microorganisms · 2025Article
- A cationic amphiphilic drug synergizes with strobilurin fungicides to control fungal-borne plant diseases.Cell chemical biology · 2025Article
- Characterizing antimicrobial activity of environmentalmSphere · 2025Article
- Inhibitory effect of copper chelators on the budding inAntimicrobial agents and chemotherapy · 2025Article
- Deciphering Fluconazole Resistance in Candida auris clade V: The Role of Efflux Pump Gene Expression and Ergosterol Pathway Mutations.Mycopathologia · 2025Article
- Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida auris is a multidrug resistant, emerging agent of fungemia in humans. Its actual global distribution remains obscure as the current commercial methods of clinical diagnosis misidentify it as C. haemulonii. Here we report the first draft genome of C. auris to explore the genomic basis of virulence and unique differences that could be employed for differential diagnosis.
resultsMore than 99.5 % of the C. auris genomic reads did not align to the current whole (or draft) genome sequences of Candida albicans, Candida lusitaniae, Candida glabrata and Saccharomyces cerevisiae; thereby indicating its divergence from the active Candida clade. The genome spans around 12.49 Mb with 8527 predicted genes. Functional annotation revealed that among the sequenced Candida species, it is closest to the hemiascomycete species Clavispora lusitaniae. Comparison with the well-studied species Candida albicans showed that it shares significant virulence attributes with other pathogenic Candida species such as oligopeptide transporters, mannosyl transfersases, secreted proteases and genes involved in biofilm formation. We also identified a plethora of transporters belonging to the ABC and major facilitator superfamily along with known MDR transcription factors which explained its high tolerance to antifungal drugs.
conclusionsOur study emphasizes an urgent need for accurate fungal screening methods such as PCR and electrophoretic karyotyping to ensure proper management of fungemia. Our work highlights the potential genetic mechanisms involved in virulence and pathogenicity of an important emerging human pathogen namely C. auris. Owing to its diversity at the genomic scale; we expect the genome sequence to be a useful resource to map species specific differences that will help develop accurate diagnostic markers and better drug targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.